ALPHA1-PROTEINASE INHIBITOR (HUMAN) 500 MG — DIN 02223643
ALPHA1-PROTEINASE INHIBITOR (HUMAN) : 500 MG · GRIFOLS THERAPEUTICS LLC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED PRE MARKET
What is ALPHA1-PROTEINASE INHIBITOR (HUMAN)?
ALPHA1-PROTEINASE INHIBITOR (HUMAN) 500 MG contains ALPHA1-PROTEINASE INHIBITOR (HUMAN) : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02223643, held by GRIFOLS THERAPEUTICS LLC, supplied as POWDER FOR SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled pre market, status dated 08-Jul-2022. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is ALPHA1-PROTEINASE INHIBITOR (HUMAN) used for?
ALPHA 1 -PROTEINASE INHIBITOR (HUMAN) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha 1 -PI (alpha 1 - antitrypsin deficiency) with clinically demonstrable panacinar emphysema.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Alfa1 Antitrypsin cost around the world?
Alfa1 Antitrypsin is listed on 2 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Austria publishes a KVP (Kassenverkaufspreis); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Austria | KVP (Kassenverkaufspreis) | 6 | 6 | EUR███.██ |
| Czechia | max producer price (ex-factory) | 2 | 6 | CZK███.██ |
12 pack listings across 8 brand entries and 2 price bases, refreshed 03 Sep 2026. Ranges span every Alfa1 Antitrypsin pack in that market, so a high figure is usually a larger pack rather than the same product.
This table is a regulatory record of where the molecule is listed. The DIN on this page is no longer authorized for sale in Canada, so Nexara does not quote it — see the alternatives above.
Is there a generic Alfa1 Antitrypsin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
4 holders have a Canadian DIN containing Alfa1 Antitrypsin, across 10 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| GRIFOLS THERAPEUTICS LLC | 5 | 1 | ALPHA1-PROTEINASE INHIBITOR (HUMAN), PROLASTIN-C, PROLASTIN-C LIQUID, PRONEXTICA LIQUID | Sourceable in Canada |
| TAKEDA CANADA INC | 1 | 1 | GLASSIA | Sourceable in Canada |
| CSL BEHRING CANADA INC | 3 | 0 | ZEMAIRA | No marketed DIN |
| CUTTER BIOLOGICAL, DIVISION OF MILES LAB INC. | 1 | 0 | PROLASTIN INJ 25.0MG/ML | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 500 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 500 mg, 1000 mg |
| Storage | under refrigeration (2°-8°C; 36°- 46°F) or at temperatures not to exceed 25°C (77°F). Freezing should be avoided |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Alfa1 Antitrypsin |
|---|---|
| ATC code | B02AB02 |
| AHFS class | 44:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02223643 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2223643 |
| Brand name | ALPHA1-PROTEINASE INHIBITOR (HUMAN) |
| Generic / active ingredient | ALPHA1-PROTEINASE INHIBITOR (HUMAN) : 500 MG |
| Market authorization holder | GRIFOLS THERAPEUTICS LLC |
| Health Canada schedule | Schedule D |
| ATC code | B02AB02 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B02AB |
| Current status | CANCELLED PRE MARKET |
| Status date | 08-Jul-2022 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Recommended dosage is 60 mg/kg body weight administered once weekly intravenously at a rate of 0.08 mL/kg/min or greater. Infusion typically takes 30 minutes.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) due to risk of severe reactions, including anaphylaxis.
Warnings and precautions
Potential for transmission of infectious agents (viruses) as it is made from human plasma. Risk of circulatory overload in at-risk patients. Immunization against Hepatitis B is recommended.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 10 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| GLASSIA | 1000 MG / 50 ML | SOLUTION | TAKEDA CANADA INC | MARKETED | 02522438 |
| PROLASTIN-C | 1000 MG | POWDER FOR SOLUTION | GRIFOLS THERAPEUTICS LLC | MARKETED | 02204606 |
| ALPHA1-PROTEINASE INHIBITOR (HUMAN) | 1 G | POWDER FOR SOLUTION | GRIFOLS THERAPEUTICS LLC | CANCELLED PRE MARKET | 02223651 |
| PROLASTIN INJ 25.0MG/ML | 25 MG | POWDER FOR SOLUTION | CUTTER BIOLOGICAL, DIVISION OF MILES LAB INC. | CANCELLED POST MARKET | 00803529 |
| PROLASTIN-C LIQUID | 1000 MG / 20 ML | SOLUTION | GRIFOLS THERAPEUTICS LLC | APPROVED | 02488787 |
| PRONEXTICA LIQUID | 1000 MG / 20 ML | SOLUTION | GRIFOLS THERAPEUTICS LLC | APPROVED | 02543028 |
| ZEMAIRA | 4000 MG | KIT ; POWDER FOR SOLUTION | CSL BEHRING CANADA INC | APPROVED | 02494760 |
| ZEMAIRA | 5000 MG | POWDER FOR SOLUTION ; KIT | CSL BEHRING CANADA INC | APPROVED | 02494779 |
| ZEMAIRA | 1000 MG | POWDER FOR SOLUTION ; KIT | CSL BEHRING CANADA INC | APPROVED | 02457911 |
2 · Same class — other molecules in ATC B02AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Alfa1 Antitrypsin | ALPHA1-PROTEINASE INHIBITOR (HUMAN) · GLASSIA · PROLASTIN INJ 25.0MG/ML · PROLASTIN-C · +3 more | 10 | 2 | Yes |
| Aprotinin | TRASYLOL · TRASYLOL INJ 10000 KIU/ML | 2 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B02A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B02AA | Aminocaproic Acid · Tranexamic Acid | 29 | 12 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is ALPHA1-PROTEINASE INHIBITOR (HUMAN) called?
The same molecule, Alfa1 Antitrypsin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| PROLASTINA | Latin | Czechia |
| RESPREEZA | Latin | Czechia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled pre market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.